Literature DB >> 24685231

β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis.

Elena Raschi1, Cecilia B Chighizola2, Claudia Grossi1, Nicoletta Ronda3, Rita Gatti4, Pier Luigi Meroni5, M Orietta Borghi2.   

Abstract

The thrombogenic effect of β2-glycoprotein I (β2GPI)-dependent anti-phospholipid antibodies (aPL) in animal models was found to be LPS dependent. Since β2GPI behaves as LPS scavenger, LPS/β2GPI complex was suggested to account for in vitro cell activation through LPS/TLR4 involvement being LPS the actual bridge ligand between β2GPI and TLR4 at least in monocytes/macrophages. However, no definite information is available on the interaction among β2GPI, LPS and endothelial TLR4 in spite of the main role of endothelial cells (EC) in clotting. To analyse at the endothelial level the need of LPS, we investigated the in vitro interaction of β2GPI with endothelial TLR4 and we assessed the role of LPS in such an interaction. To do this, we evaluated the direct binding and internalization of β2GPI by confocal microscopy in living TLR4-MD2 transfected CHO cells (CHO/TLR4-MD2) and β2GPI binding to CHO/TLR4-MD2 cells and human umbilical cord vein EC (HUVEC) by flow cytometry and cell-ELISA using anti-β2GPI monoclonal antibodies in the absence or presence of various concentrations of exogenous LPS. To further investigate the role of TLR4, we performed anti-β2GPI antibody binding and adhesion molecule up-regulation in TLR4-silenced HUVEC. Confocal microscopy studies show that β2GPI does interact with TLR4 at the cell membrane and is internalized in cytoplasmic granules in CHO/TLR4-MD2 cells. β2GPI binding to CHO/TLR4-MD2 cells and HUVEC is also confirmed by flow cytometry and cell-ELISA, respectively. The interaction between β2GPI and TLR4 is confirmed by the reduction of anti-β2GPI antibody binding and by the up-regulation of E-selectin or ICAM-1 by TLR4 silencing in HUVEC. β2GPI binding is not affected by LPS at concentrations comparable to those found in both β2GPI and antibody preparations. Only higher amount of LPS that can activate EC and up-regulate TLR4 expression are found to increase the binding. Our findings demonstrate that β2GPI interacts directly with TLR4 expressed on EC, and that such interaction may contribute to β2GPI-dependent aPL-mediated EC activation. At variance of monocytic cells, we also showed a threshold effect for the action of LPS, that is able to enhance anti-β2GPI antibody EC binding only at cell activating concentrations, shown to increase TLR4 expression. This in vitro model may explain why LPS behaves as a second hit increasing the expression of β2GPI in vascular tissues and triggering aPL-mediated thrombosis in experimental animals.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-β2-glycoprotein I antibodies; Endothelial cells; Innate immunity; LPS; Toll-like receptor 4; β2-Glycoprotein I

Mesh:

Substances:

Year:  2014        PMID: 24685231     DOI: 10.1016/j.jaut.2014.03.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

Review 1.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review.

Authors:  Maximiliano Javier Jiménez-Dalmaroni; M Eric Gerswhin; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2015-08-20       Impact factor: 9.754

2.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

3.  Anti-β2GPI/β2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies.

Authors:  Wenjing Zhang; Caijun Zha; Xiumin Lu; Ruichun Jia; Fei Gao; Qi Sun; Meili Jin; Yanhong Liu
Journal:  Front Med       Date:  2019-02-28       Impact factor: 4.592

Review 4.  Epigenetics and Systemic Lupus Erythematosus: Unmet Needs.

Authors:  Pier Luigi Meroni; Alessandra Emiliana Penatti
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

5.  Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study.

Authors:  Ruchi Shah; Yaqub Nadeem Mohammed; Tracy J Koehler; Jasmeet Kaur; Margarita Toufeili; Priyanjali Pulipati; Ahmed Alqaysi; Ali Khan; Mahrukh Khalid; Yi Lee; Parveen Dhillon; Anna Thao Dan; Nicholas Kumar; Monica Bowen; Anupam A Sule; Geetha Krishnamoorthy
Journal:  PLoS One       Date:  2022-07-14       Impact factor: 3.752

Review 6.  Autoimmunity in 2014.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-10       Impact factor: 8.667

7.  Antiphospholipid Antibodies Inhibit Trophoblast Toll-Like Receptor and Inflammasome Negative Regulators.

Authors:  Melissa J Mulla; Ingrid C Weel; Julie A Potter; Stefan M Gysler; Jane E Salmon; Maria T S Peraçoli; Carla V Rothlin; Lawrence W Chamley; Vikki M Abrahams
Journal:  Arthritis Rheumatol       Date:  2018-04-25       Impact factor: 10.995

Review 8.  New Insights in the Pathophysiology of Antiphospholipid Syndrome.

Authors:  Anastasia Sacharidou; Philip W Shaul; Chieko Mineo
Journal:  Semin Thromb Hemost       Date:  2017-01-27       Impact factor: 6.398

Review 9.  The Role of TLR4 on B Cell Activation and Anti-β2GPI Antibody Production in the Antiphospholipid Syndrome.

Authors:  Si Cheng; Haibo Wang; Hong Zhou
Journal:  J Immunol Res       Date:  2016-10-27       Impact factor: 4.818

10.  Bilateral adrenal hemorrhage in the background of Escherichia coli sepsis: a case report.

Authors:  Jahanzaib Khwaja
Journal:  J Med Case Rep       Date:  2017-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.